Non-penetrating filtering surgery with MMC

Article

Non-penetrating filtering surgery with intraoperative mitomycin C (MMC) and without a scleral implant, can provide reasonable intraocular pressure (IOP) control.

Non-penetrating filtering surgery with intraoperative mitomycin C (MMC) and without a scleral implant, can provide reasonable intraocular pressure (IOP) control, according to Esther Arranz-Marquez and co-workers from the Vissum Corporacion Oftalmologica de Madrid, Spain.

A prospective trial enrolled 131 patients with primary open angle glaucoma (POAG) to undergo non-penetrating filtering surgery with MMC and without an implant. Patients were followed-up at one day and one, three, six, nine and 12 months postoperatively.

Mean preoperative IOP was 20.2±5.2 mmHg. At each follow-up a reduction in IOP was recorded (p=0.001): 12.3±4.2, 13.7±4.6, 13.7±3.6, 14.2±4.0, 14.1±3.6 at one, three, six, nine and 12 months, respectively. Further, the mean number of medications reduced from 1.8±0.7 to 0.1±0.4 12 months postoperatively. Goniopuncture was carried out in 31 eyes and three eyes were re-operated on due to inadequate IOP control.

At the study's conclusion, the authors believed that this procedure offers reasonable IOP control with few postoperative complications.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.